A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

计划入组 50 人 · 首次发布于 2019 年 3 月 21 日

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

计划入组 89 人 · 首次发布于 2008 年 7 月 4 日

GLP-1 RA for Stage 1 Type 1 Diabetes

计划入组 15 人 · 首次发布于 2026 年 2 月 24 日

TKM-PLK1

Plk-1 inhibitors (cancer)

DNX-1000

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Rigosertib Achieves 80% Response Rate in First Clinical Trial for Rare RDEB-Associated Skin Cancer

Gilead's Lenacapavir Shows Promise in HIV Prevention, While GLP-1s Studied for Type 1 Diabetes

GLP-1 Drug Use Surges Among Type 1 Diabetes Patients Despite Safety Concerns